Several approaches are available to improve health and quality of life in allergic patients
A new systematic review and narrative synthesis published in Pediatric Allergy and Immunology set out to comprehensively describe current and exploratory therapeutic options for managing tree nut allergy.
Researchers searched three bibliographic databases for studies published until January 2024, looking for active treatments of IgE-mediated allergy to tree nuts (almond, Brazil nut, cashew, hazelnut, macadamia, pecan, pistachio and walnut). The authors identified a total of 19 studies that met their criteria: three studies that investigated sublingual immunotherapy, five that studied oral immunotherapy to a single tree nut, and six that used multi-food oral immunotherapy.
The authors found that there is growing evidence about implementing tree nut immunotherapy in clinical practice. They identified three main strategies that have been tested in clinical trials and real-life studies: sublingual immunotherapy, oral immunotherapy (single or multiple, with or without omalizumab), and the use of monoclonal antibodies interfering with allergic responses. Although further research is needed, the strategies identified in this study may ameliorate the burden of tree nut allergy on patients’ health and quality of life.
Pasioti, M., Xepapadaki, P., Mathioudakis, A. G., Lakoumentas, J., Efstathiou, E., & Papadopoulos, N. G. (2024). Current options in the management of tree nut allergy: A systematic review and narrative synthesis. Pediatric Allergy and Immunology, 35(5), e14132.